Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / FDA Approves Moderna's First mRNA Flu Vaccine
Regulatory regulatory approval

FDA Approves Moderna's First mRNA Flu Vaccine

Analysis based on 105 articles · First reported Aug 05, 2026 · Last updated Aug 07, 2026

Sentiment
60
Attention
7
Articles
105
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The approval is a significant milestone for Moderna, potentially opening a new revenue stream as COVID-19 vaccine sales decline. It may also pressure competitors in the flu vaccine market, though analysts expect meaningful sales only from 2027 due to missed contracting cycles.

Pharmaceuticals Biotechnology Healthcare
Event Summary

On August 5, 2026, the U.S. United States — Food and Drug Administration (FDA) approved Moderna's mFLUSIVA (mRNA-1010), the first mRNA-based seasonal influenza vaccine, for adults aged 50 and older. The approval covers traditional approval for ages 50-64 and accelerated approval for ages 65 and older, contingent on a postmarketing study. Clinical trials involving over 40,000 adults showed mFLUSIVA was about 27% more effective than a standard-dose flu vaccine. The approval follows a contentious review process, including an initial refusal-to-file by former FDA official Vinay Prasad, which was reversed after public backlash. The vaccine is expected to be available for the 2026-2027 flu season, competing with existing flu vaccines from Sanofi, GSK plc, CSL Limited — CSL Limited, and AstraZeneca. Moderna aims to leverage its mRNA platform to address flu and other diseases, despite ongoing skepticism from Health Secretary Robert F. Kennedy Jr. and reduced federal funding for mRNA research.

Key Actions
100 United States — Food and Drug Administration approved Moderna
97 Moderna sought approval United States — Food and Drug Administration
82 United States — Centers for Disease Control and Prevention made changes
80 United States — United States Department of Health and Human Services canceled projects United States — Biomedical Advanced Research and Development Authority
77 United States — Food and Drug Administration refused application Moderna
70 United States — United States Department of Health and Human Services canceled projects
68 Robert F. Kennedy Jr. installed replacements United States — Centers for Disease Control and Prevention
65 United States — Food and Drug Administration accepted application Moderna
60 United States — Food and Drug Administration reversed course Moderna
60 Robert F. Kennedy Jr. said MMR vaccine is effective
60 Robert F. Kennedy Jr. canceled mRNA vaccine projects United States — Biomedical Advanced Research and Development Authority
60 United States — Centers for Disease Control and Prevention rolled back vaccine recommendations
50 Moderna agreed to run study United States — Food and Drug Administration
50 Robert F. Kennedy Jr. installed replacements United States — Centers for Disease Control and Prevention
45 Moderna withdrew combined flu-COVID shot United States — Food and Drug Administration
+ 12 more actions View on Dashboard
Entities Involved
govactor
United States — Food and Drug Administration
The FDA granted approval for mFLUSIVA, marking a regulatory milestone and demonstrating its role in vaccine oversight despite internal controversies.
Importance 100.0 Sentiment 60.0
stock
Moderna
Moderna received its fourth FDA-approved product and first mRNA flu vaccine, boosting its commercial prospects and validating its mRNA platform.
Importance 100.0 Sentiment 80.0
per
Stéphane Bancel
As CEO, Bancel championed the vaccine and highlighted its importance for seniors and the company's future.
Importance 70.0 Sentiment 70.0
cnt
United States
The U.S. gains a new flu vaccine option, potentially improving public health outcomes for older adults.
Importance 60.0 Sentiment 50.0
per
Robert F. Kennedy Jr.
Kennedy's skepticism of mRNA vaccines influenced funding cuts and regulatory scrutiny, but the approval proceeded despite his opposition.
Importance 60.0 Sentiment -40.0
govactor
United States — Advisory Committee on Immunization Practices
ACIP's inability to convene due to a court ruling means no formal recommendation for mFLUSIVA, potentially limiting insurance coverage and public distribution despite FDA approval.
Importance 50.0 Sentiment 10.0
govactor
United States — United States Department of Health and Human Services
HHS, under Kennedy, canceled mRNA research funding, creating a challenging environment for mRNA vaccine development.
Importance 50.0 Sentiment -30.0
per
Vinay Prasad
Prasad's refusal-to-file decision was reversed, and he later left the FDA; his actions highlighted regulatory tensions.
Importance 50.0 Sentiment -30.0
govactor
United States — Centers for Disease Control and Prevention
CDC's advisory committee may recommend mFLUSIVA, which would influence coverage and uptake; its recommendation is pending.
Importance 40.0 Sentiment 50.0
stock
Sanofi
Sanofi's high-dose flu vaccine served as a comparator in trials; the new mRNA vaccine may compete with its products.
Importance 40.0 Sentiment -20.0
per
Marty Makary
Makary, former FDA Commissioner, faced criticism for vaccine scrutiny and resigned amid controversies.
Importance 40.0 Sentiment -30.0
per
Donald Trump
As President, Trump's administration has overseen vaccine policy changes and FDA leadership, influencing the regulatory climate.
Importance 30.0 Sentiment 0.0
stock
Pfizer
Pfizer, a rival in mRNA vaccines, may face competitive pressure as Moderna expands its mRNA platform into flu.
Importance 30.0 Sentiment -10.0
govactor
United States — Biomedical Advanced Research and Development Authority
BARDA's mRNA vaccine development activities were wound down by HHS, reducing federal support for mRNA technology. This approval may partially offset that setback.
Importance 30.0 Sentiment -20.0
alliance
European Union
The EU is reviewing mFLUSIVA, which could expand Moderna's market access.
Importance 30.0 Sentiment 40.0
+ 16 more entities View on Dashboard
Relationships
United States — Food and Drug Administration related ↔ Moderna
United States — Food and Drug Administration related ↔ United States
United States — Food and Drug Administration related ↔ Robert F. Kennedy Jr.
United States — Food and Drug Administration related ↔ United States — United States Department of Health and Human Services
United States — Food and Drug Administration related ↔ Vinay Prasad
United States — Food and Drug Administration related ↔ United States — Centers for Disease Control and Prevention
United States — Food and Drug Administration related ↔ Sanofi
Moderna related ↔ Stéphane Bancel
Moderna related ↔ United States
Moderna related ↔ Robert F. Kennedy Jr.
Moderna related ↔ Vinay Prasad
Moderna related ↔ United States — Centers for Disease Control and Prevention
Stéphane Bancel related ↔ United States — Centers for Disease Control and Prevention
United States related ↔ Robert F. Kennedy Jr.
United States related ↔ United States — Advisory Committee on Immunization Practices
+ 11 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.